Our Vision

Improving outcomes for cancer patients more rapidly

The aim of the Cancer Group is to improve outcomes for cancer patients more rapidly by speeding up the evaluation of new cancer therapies and preventative strategies through the development and application of novel clinical research methods.

Improving outcomes for cancer patients globally

Cancer incidence is increasing rapidly, and disproportionately in low and middle income countries predominantly due to population growth and changing lifestyles and we are committed to developing affordable and less toxic therapies that are relevant across all economic settings.


Our Programmes

Improving cancer survival and decreasing cancer morbidity.

The overarching aim of our cancer research is to improve cancer survival and decrease cancer morbidity by designing and implementing innovative late phase studies that have a major impact on clinical practice. Our work consists of two linked programmes encompassing a spectrum of cancer clinical trials activity.


Evaluating New Health Technologies

We specialise in adaptive multi-arm multi-stage (MAMS), umbrella and basket trial designs and in this programme we focus on the opportunities that discovery science and new technologies bring to improve cancer outcomes.

Developing Existing Health Technologies to Deliver More Affordable and Effective Care

This programme focusses on developing existing health technologies. For example, evaluating drugs that are already licensed for other indications (repurposing) or alternative (more affordable) scheduling regimens for newer therapies. We address important clinical questions that others are unlikely to tackle, due to a challenging clinical scenario, geographical setting and/or lack of pharmaceutical industry interest.

Our Studies in Cancer


Can regular aspirin use after standard therapy prevent disease recurrence and prolong survival in participants with common, non-metastatic solid tumours?


A trial that aims to find the best treatment for people with advanced prostate cancer.


Aiming to find out whether taking one drug (durvalumab) or a combination of two drugs (durvalumab and tremelimumab) can prevent or delay kidney cancer coming back.


Identifying the most effective treatments for patients with different genetic sub-types of colorectal (bowel) cancer.


Speeding up the evaluation of therapies for metastatic hormone-sensitive prostate cancer.

All Cancer Studies

Our unit have been conducting trials in cancer for over 20 years.

View list of Cancer studies.